Eric J. Loumeau Sells 2,500 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock
AnaptysBio, Inc. (NASDAQ:ANAB – Get Rating) COO Eric J. Loumeau sold 2,500 shares of the company’s stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $24.00, for a total value of $60,000.00. Following the completion of the sale, the chief operating officer now owns 523 shares in the company, valued at $12,552. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
AnaptysBio stock traded down $0.72 during mid-day trading on Friday, hitting $22.00. The stock had a trading volume of 481,140 shares, compared to its average volume of 259,248. The stock has a 50-day simple moving average of $22.27 and a two-hundred day simple moving average of $28.09. The stock has a market capitalization of $620.09 million, a PE ratio of -7.99 and a beta of 0.19. AnaptysBio, Inc. has a 12 month low of $18.20 and a 12 month high of $37.89.
AnaptysBio (NASDAQ:ANAB – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.32). AnaptysBio had a negative net margin of 143.46% and a negative return on equity of 20.44%. Research analysts forecast that AnaptysBio, Inc. will post -4.27 earnings per share for the current year.
A number of institutional investors have recently bought and sold shares of ANAB. Frazier Life Sciences Management L.P. bought a new position in AnaptysBio in the first quarter valued at about $22,259,000. Deep Track Capital LP acquired a new position in AnaptysBio in the first quarter valued at about $13,824,000. Point72 Asset Management L.P. acquired a new position in AnaptysBio in the fourth quarter valued at about $8,936,000. Woodline Partners LP lifted its stake in AnaptysBio by 36.7% in the first quarter. Woodline Partners LP now owns 833,927 shares of the biotechnology company’s stock valued at $20,631,000 after buying an additional 223,946 shares during the period. Finally, Laurion Capital Management LP acquired a new position in AnaptysBio in the fourth quarter valued at about $6,081,000.
ANAB has been the topic of a number of analyst reports. HC Wainwright upped their price target on AnaptysBio from $43.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, March 7th. StockNews.com cut AnaptysBio from a “hold” rating to a “sell” rating in a research report on Tuesday, April 26th. Guggenheim cut AnaptysBio from a “buy” rating to a “neutral” rating in a report on Tuesday, March 22nd. Zacks Investment Research upgraded AnaptysBio from a “strong sell” rating to a “hold” rating in a report on Thursday, March 17th. Finally, Wedbush restated a “neutral” rating on shares of AnaptysBio in a report on Monday, March 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $40.00.
AnaptysBio Company Profile (Get Rating)
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider AnaptysBio, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and AnaptysBio wasn’t on the list.
While AnaptysBio currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.